Uncategorized
Auven Therapeutics completes enrollment in phase 3 study of Seciera for dry eye
Auven Therapeutics completed enrollment in a phase 3 confirmatory study of Seciera for the treatment of dry eye disease, according to a press release.Seciera (OTX-101) is a novel patented nanomicellar formulation of cyclosporine. The multicenter, randomized, double-masked, placebo-controlled, two-arm phase 3 trial enrolled 747 patients with dry eye disease at 47 investigational sites in the United States.